Clinical Trials · NCT04660643
A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight for the Maintenance of Weight Loss
- Phase
- Phase 3
- Recruitment status
- Completed
- Sponsor
- Eli Lilly and Company
- Enrollment
- 783
- Start date
- Mar 2021
- Locations
- 70 sites, 5 countries
- Primary endpoint
- Percent Change From Randomization in Body Weight at Week 88